EOC Pharma raises $32M series B

EOC Pharma Group (Shanghai, China) raised $32 million in a series B round led by new investor Taikang. Fellow new investor H&Q Asia Pacific also participated, as did existing investor Sequoia China.

EOC Pharma, a spin-off of the oncology division of Eddingpharm Inc. (Hong Kong, China), in-licenses candidates to develop and commercialize in China...